Boston Scientific (BSX) Extends Losing Streak: What Tuesday’s Close Means Before the Bell on December 10, 2025

Boston Scientific Corporation (NYSE: BSX) heads into Wednesday’s U.S. trading session looking bruised but far from broken.

On Tuesday, December 9, 2025, Boston Scientific stock slipped about 1.4% to roughly $92.5 per share, on heavier‑than‑usual volume of around 12.7 million shares, versus an average near 8.9 million. ^[1] That marked another down day in an early‑December pullback that has left BSX trading at the bottom of its 50‑day range and about 15% below its 52‑week high of $109.50, set in September. ^[2]

After the bell, extended trading in BSX was quiet, with the stock hovering in a tight band around $92.5–$92.6, leaving the broader downtrend intact but not accelerating. ^[3]

Here’s what happened on December 9, what the freshest research and forecasts are saying, and what traders and long‑term investors should watch before the market opens on Wednesday, December 10, 2025.

How Boston Scientific Stock Traded on December 9, 2025

Price action and volume

• Close: About $92.5 per share
• Move on the day: roughly ‑1.4%
• Intraday range: approximately $92.26–$94.84 ^[4]
• Volume: ~12.7 million shares vs average ~8.9 million ^[5]

That combination — price down, volume up — is textbook “distribution”: sellers were more enthusiastic than buyers.

MarketBeat’s snapshot shows BSX now sitting right at the bottom of its 50‑day range ($92.52–$104.99) and comfortably above its 52‑week low of $85.98, but well below its prior high of $109.50. ^[6]

Despite the recent slide, BSX still shows modestly positive performance over the past year, with different data providers putting the 12‑month gain in the low‑single‑digit to high‑single‑digit percentage range. ^[7]

After‑hours trading

In extended trading on Tuesday evening, different feeds pegged BSX around $92.5–$92.6, effectively flat versus the regular‑session close. ^[8]

Crucially:

• No new company press release hit the Boston Scientific investor site on December 9. Recent official releases concentrate on earlier announcements like the 2025 Investor Day and the launch of Endura Weight Loss Solutions. ^[9]
• The lack of fresh, company‑specific negative news suggests the move is largely about valuation, sector sentiment, and positioning, not a sudden deterioration in fundamentals.

Why Has BSX Been Under Pressure?

1. A multi‑week pullback after a strong run

Simply Wall St notes that Boston Scientific shares are down roughly 4% over the past week and about 13% over the past three months, even though they remain positive year to date and have almost doubled shareholders’ money over the last three years. ^[10]

That pattern — big multi‑year gains, then a sharp but still moderate drawdown — fits the “momentum cool‑down” story more than a collapse.

2. Valuation fatigue

Several recent analyses converge on the same basic theme: fantastic growth, expensive stock.

• Benzinga points out that BSX’s price‑to‑earnings (P/E) ratio is around 50, slightly above the already‑rich Health Care Equipment & Supplies industry P/E near 48.6, after the stock rose over the past year but slipped about 9% in the last month. ^[11]
• MarketBeat calculates BSX’s current P/E near 49.5, materially higher than both the broader market (around 39) and the medical sector average (about 38). ^[12]
• Simply Wall St’s narrative flags a P/E near 50 compared with peer averages closer to 40, arguing that although their discounted‑cash‑flow model sees fair value well above the current price, the multiple leaves “limited margin for error” if growth slows. ^[13]

In other words: the stock is fundamentally strong but priced like it — and in a skittish tape, high‑multiple names often get hit first.

3. Sector nerves and regulatory overhangs

Morpher’s AI‑driven commentary on BSX’s slide into early December highlights broader medtech jitters:

• A recent FDA panel vote against a novel heart‑failure shunt from Johnson & Johnson added caution around complex cardiovascular devices, a space where Boston Scientific is a major player. ^[14]
• Competitive noise — including new surgical robotics players in China — and attention shifting to other big medical device names have also weighed on sentiment. ^[15]

Those factors don’t directly hit Boston Scientific’s earnings today, but they raise perceived risk, which matters when a stock already carries a premium valuation.

Fundamentals: The Growth Story Is Very Much Intact

Under the hood, Boston Scientific’s operating story remains notably strong.

Third‑quarter 2025: another beat, guidance raised

In October, Boston Scientific reported Q3 2025 results that were, frankly, impressive:

• Revenue: about $5.07 billion, up roughly 20% year over year, topping expectations around $4.97 billion. ^[16]
• Cardiovascular sales: approximately $3.34 billion, more than 22% growth. ^[17]
• Electrophysiology (EP): around $865 million, with growth in the low 60% range, driven by the FARAPULSE pulsed‑field ablation system and increased adoption of the OPAL HDx mapping platform. ^[18]
• Watchman left‑atrial‑appendage closure device sales have grown in the mid‑30% range year over year, underscoring strength in stroke‑prevention procedures. ^[19]
• Adjusted EPS: about $0.75, ahead of consensus near $0.71; operating margin expanded by roughly 80 basis points to 28%. ^[20]

On the back of that, management raised full‑year 2025 EPS guidance to $3.02–$3.04, up from $2.95–$2.99, and guided Q4 EPS to $0.77–$0.79, slightly above Wall Street estimates. ^[21]

So the backdrop into Tuesday’s decline is earnings and revenue that are actually running ahead of expectations.

PFA and electrophysiology: the growth engine

Boston Scientific’s electrophysiology franchise sits at the heart of the bull case:

• FARAPULSE — a pulsed‑field ablation (PFA) system for atrial fibrillation — is seeing rapid adoption in the U.S. and internationally. Management and outside analysts point to EP sales growth of around 60–64% year over year in Q3. ^[22]
• In July 2025, the FDA granted expanded labeling for FARAPULSE to include pulmonary vein and posterior wall ablation in persistent AF, widening its eligible patient pool. ^[23]
• The company expects global PFA penetration to reach roughly 50% by the end of 2025 and approach 80% by 2028, and is preparing next‑generation products like the FARAPOINT PFA catheter and the OPTIMIZE trial, which integrates OPAL mapping with the AI‑driven Cortex algorithm. ^[24]

This is exactly the kind of high‑growth, high‑margin niche investors usually love — which helps explain why the multiple is elevated.

Aggressive R&D and long‑term targets

A recent Yahoo‑syndicated article, summarized by SwingTradeBot, highlights that management is talking openly about:

• Sustained 8–10% annual revenue growth,
• Ongoing margin expansion, and
• Double‑digit earnings growth,

supported by reinvesting roughly 9–10% of revenue into research and development across electrophysiology, structural heart, and minimally invasive portfolios. ^[25]

If those targets are even close to right, BSX looks like a long‑duration growth story — which again is wonderful in steady markets and painful when rates or sentiment move the wrong way.

M&A and footprint expansion

Boston Scientific has also been buying more future growth:

• Nalu Medical: In October, the company agreed to buy the remaining equity in Nalu Medical for about $533 million, adding a miniaturized, smartphone‑controlled peripheral nerve stimulation system for chronic pain to its neuromodulation portfolio. The deal is expected to close in the first half of 2026 and become marginally profitable by 2027. ^[26]
• Elutia BioEnvelope: In September, Boston Scientific struck an $88 million deal to acquire Elutia’s Elupro and Cangaroo bioenvelope products, aimed at reducing complications after pacemaker and defibrillator implants. ^[27]
• Endura Weight Loss Solutions: Earlier in 2025, the company launched Endura, a brand platform for minimally invasive weight‑loss procedures (including endoscopic sleeve gastroplasty and intragastric balloon), expanding its reach into obesity‑related interventions. ^[28]
• Maple Grove campus: In early December, Boston Scientific purchased a 400,000‑square‑foot facility in Maple Grove, Minnesota, for about $188.8–$190 million. The site will serve as an R&D lab, office space and training hub, with the company planning to vacate its Minnetonka campus by mid‑2026. ^[29]

These moves reinforce the long‑term growth runway — but they also remind investors that Boston Scientific is actively deploying capital, which can sharpen focus on valuation when the share price stumbles.

What the Latest December 9 Research and Commentary Is Saying

A cluster of fresh articles and notes on December 9 focused on valuation, momentum and risk‑reward.

Valuation deep dives

1. Simply Wall St – “Is the Recent Pullback Creating a New Valuation Opportunity?”
   • Points out BSX is down about 13% over three months, even as earnings continue to grow at a double‑digit pace. ^[30]
   • Their most‑followed narrative pegs fair value near $126.5 per share, implying roughly 25–26% upside from recent levels. ^[31]
   • However, they stress that a P/E around 50, versus peer averages in the high‑30s, means expectations are already high, and any growth wobble could trigger further derating. ^[32]
2. Benzinga – “A Look Into Boston Scientific Inc’s Price Over Earnings”
   • Notes BSX trading around $94 intraday on December 9, up slightly in that session, but down about 9.4% over the past month and up only ~2.6% over the past year. ^[33]
   • Emphasizes a P/E near 50.2, slightly higher than the sector’s roughly 48.6, arguing that the stock may be overvalued relative to its industry, even if growth remains solid. ^[34]
3. Simply Wall St – “A Look at Boston Scientific’s Valuation Following Breakout Electrophysiology Growth and Expanded FDA Approval”
   • Reiterates a fair value estimate of $126.48 and labels BSX “about 20.9% undervalued” by their models. ^[35]
   • Highlights 13.3% total shareholder return over the past year and 163% over five years, stressing the compounding effect of long‑term holding. ^[36]
   • But also underlines a P/E around 53x, versus an industry average near 28x and a “fair” multiple they estimate under 40x, warning that investors are paying a steep premium. ^[37]

Factor and “Smart Score” views

Smartkarma’s December 9 note, “Boston Scientific Corporation’s Stock Price Dips to $93.84, Facing a 3.77% Decline: Time to Buy or Bail?”, highlights: ^[38]

• A prior session where BSX fell 3.77% to $93.84 on volume near 14.65 million shares, yet kept a year‑to‑date gain over 9%.
• A composite “Smart Score” around 3.2 out of 5, with strong marks for growth and momentum, weaker marks for dividends and value — effectively summarizing BSX as a growth‑oriented, not‑cheap stock with decent resilience.

Analyst Ratings and Targets Heading Into December 10

Despite the recent wobble in the share price, Wall Street still leans strongly bullish on Boston Scientific.

• MarketBeat shows a consensus rating of “Buy”, based on 2 Strong Buy, 21 Buy, and 2 Hold ratings, with no Sell calls. ^[39]
• The average 12‑month price target on MarketBeat is $123.77, about 34% above the current price near $92.5. ^[40]
• Investing.com’s aggregated data is even more upbeat, listing an average target around $126.5, a high estimate of $140 and a low near $99, with 32 analysts overall rating BSX a “Strong Buy” and estimating upside in the mid‑30% range. ^[41]
• A recent Needham note reiterates a Buy rating with a $121 target, while RBC maintains an “Outperform” rating with a $125 target, both implying healthy upside from the low‑90s. ^[42]
• Zacks classifies BSX as a Rank #2 (Buy), and notes that the stock trades at a forward five‑year P/E of about 29x, versus an industry average near 20x — again, expensive, but backed by higher growth expectations. ^[43]

The consensus message: “We like the company, we like the growth, we know it’s not cheap.”

Options Market: A Cautious Short‑Term Signal

One of the more notable December signals came not from equities but from options.

TipRanks, via TheFly, flagged “put volume heavy and directionally bearish” in BSX: ^[44]

• Roughly 3,140 puts traded, about 5× normal.
• The most active contracts were January 2026 $92.50 puts and near‑dated December 12 $98 calls, with combined volume near 3,600 contracts.
• The put/call ratio sat around 2.4, and at‑the‑money implied volatility jumped nearly 6 volatility points in the session.
• Next earnings date is expected on February 4, making those Jan‑26 puts a direct play (or hedge) on a bumpy road into results.

Heavy put activity doesn’t necessarily mean the crowd is outright bearish — it may reflect hedging by long shareholders locking in gains from the last few years. But it does tell you that near‑term uncertainty is elevated, which matters for traders eyeing overnight or multi‑day positions.

Quant and Model‑Based Forecasts

Beyond Wall Street’s human analysts, several quant and model‑driven platforms have weighed in:

• CoinCodex projects that BSX could see low single‑digit percentage gains over the coming weeks, with one scenario pointing to a move into the mid‑$90s to low‑$100s by early January 2026. They classify the near‑term technical sentiment as “Bearish”, and their Fear & Greed Index reading of 39 (“Fear”) indicates a cautious tape. ^[45]
• Morpher’s AI model recently tagged BSX with a “down 2.3% today” forecast on December 8, pointing to negative sector news and shifting investor attention as drivers. At the same time, the same platform highlights a bullish long‑term case built on 8–10% annual revenue growth, significant margin expansion, and double‑digit EPS CAGR, driven by products like FARAPULSE and Watchman. ^[46]

The machines, in short, look nervous short term, constructive long term — not wildly different from human analysts.

Macro Backdrop: Rates and Risk Appetite on December 10

Wednesday’s session doesn’t take place in a vacuum.

• The U.S. Federal Reserve is scheduled for a rate decision on December 10, 2025, with the policy rate currently around 4.0%. ^[47]
• High‑multiple growth names like Boston Scientific are particularly sensitive to any hint that rates may stay higher for longer or that real yields might move up, compressing valuation multiples.

If the Fed’s wording leans hawkish, medtech and other growth stocks could see another bout of pressure — even if company‑specific fundamentals haven’t changed.

What to Watch Before the Market Opens on December 10, 2025

Here’s a practical checklist heading into Wednesday’s trading:

1. Premarket price and volume

Investing.com data shows BSX’s latest pre‑market indication just under $94, with relatively modest pre‑market volume around a few thousand shares and a small negative change versus the prior reference price. ^[48]

Key things to watch:

• Does BSX bounce from Tuesday’s close, or does pre‑market trading push it further below the 50‑day range low?
• Is volume light and noisy (often meaningless) or unusually heavy, hinting at institutions adjusting positions ahead of the open?

2. Sector and index tone

Keep an eye on:

• The broader S&P 500 and healthcare / medtech ETFs at the open; BSX has historically moved with sector risk sentiment. ^[49]
• Any overnight headlines from medtech peers like Abbott, Medtronic or Johnson & Johnson that might color sentiment toward cardiac and electrophysiology devices. ^[50]

3. Options pricing at the open

Given the recent spike in puts and implied volatility, traders should see whether:

• Implied volatility stays elevated (options still pricey, market nervous), or
• IV drifts down as the stock stabilizes (suggesting some of that hedging demand has cooled). ^[51]

This won’t matter much for a long‑term shareholder, but it’s essential for short‑term options traders.

4. Technical levels

From MarketBeat’s snapshot: ^[52]

• Immediate support: the 50‑day range low around $92.5 and, below that, the 52‑week low near $86.
• Near‑term resistance: Tuesday’s intraday high near $94–$95, followed by the round‑number $100 level, which also lines up with where multiple valuation screens start to look a bit less stretched.

A decisive break below the recent range on strong volume would signal that the pullback has more room to run; a bounce with improving breadth across medtech could suggest the selling is more of a shakeout than the start of a full trend reversal.

Bottom Line: How to Frame BSX Going Into Dec. 10

Putting it all together:

• Price action: BSX has sold off for several sessions, sits around 15% below its 52‑week high, and trades at the bottom of its short‑term range, with heavy recent volume and bearish options positioning into February. ^[53]
• Fundamentals: Revenue, earnings and margins are strong and improving, especially in electrophysiology, structural heart and minimally invasive therapies. Recent deals (Nalu, Elutia) and launches (Endura) reinforce a long runway of innovation. ^[54]
• Valuation: Almost every serious analysis agrees BSX is expensive on traditional multiples, even as DCF‑style fair‑value models argue for 20–30% upside from today’s price. ^[55]
• Consensus: Wall Street’s stance remains solidly bullish, but quants and options markets are sending a more cautious short‑term message.

For short‑term traders, Wednesday’s open and early trading will be about whether BSX can hold the low‑90s, how the Fed tone feels, and whether options volatility cools off.

For long‑term investors, the key question is whether you’re comfortable owning a high‑quality medtech compounder at a premium multiple, through the inevitable bumps that come with higher rates, regulatory noise and competition.

References

1. www.marketbeat.com, 2. www.marketbeat.com, 3. www.marketbeat.com, 4. www.marketbeat.com, 5. www.marketbeat.com, 6. www.marketbeat.com, 7. www.benzinga.com, 8. www.marketbeat.com, 9. news.bostonscientific.com, 10. simplywall.st, 11. www.benzinga.com, 12. www.marketbeat.com, 13. simplywall.st, 14. www.morpher.com, 15. www.morpher.com, 16. www.reuters.com, 17. www.reuters.com, 18. finviz.com, 19. www.medtechdive.com, 20. www.reuters.com, 21. www.reuters.com, 22. finviz.com, 23. news.bostonscientific.com, 24. finviz.com, 25. swingtradebot.com, 26. www.prnewswire.com, 27. elutia.com, 28. news.bostonscientific.com, 29. finance-commerce.com, 30. simplywall.st, 31. simplywall.st, 32. simplywall.st, 33. www.benzinga.com, 34. www.benzinga.com, 35. www.webull.com, 36. www.webull.com, 37. www.webull.com, 38. www.smartkarma.com, 39. www.marketbeat.com, 40. www.marketbeat.com, 41. www.investing.com, 42. www.gurufocus.com, 43. finviz.com, 44. www.tipranks.com, 45. coincodex.com, 46. www.morpher.com, 47. www.investing.com, 48. www.investing.com, 49. www.investing.com, 50. www.medtechdive.com, 51. www.tipranks.com, 52. www.marketbeat.com, 53. www.marketbeat.com, 54. www.reuters.com, 55. www.marketbeat.com